Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lessened its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 14.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,580 shares of the company’s stock after selling 4,300 shares during the quarter. Janus Henderson Group PLC’s holdings in Twist Bioscience were worth $1,156,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Benjamin Edwards Inc. raised its position in Twist Bioscience by 10,120.2% during the third quarter. Benjamin Edwards Inc. now owns 12,673 shares of the company’s stock worth $572,000 after acquiring an additional 12,549 shares during the last quarter. Fred Alger Management LLC increased its stake in shares of Twist Bioscience by 17.1% during the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after purchasing an additional 112,272 shares in the last quarter. Verition Fund Management LLC raised its position in shares of Twist Bioscience by 315.5% during the 3rd quarter. Verition Fund Management LLC now owns 25,093 shares of the company’s stock worth $1,134,000 after purchasing an additional 19,054 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after buying an additional 363 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Twist Bioscience by 128.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares during the last quarter.

Insider Buying and Selling

In related news, insider Dennis Cho sold 659 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $27,388.04. Following the transaction, the insider now owns 94,481 shares in the company, valued at approximately $3,926,630.36. This trade represents a 0.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Paula Green sold 1,057 shares of Twist Bioscience stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92. Following the transaction, the senior vice president now directly owns 121,013 shares in the company, valued at approximately $5,029,300.28. This trade represents a 0.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 101,787 shares of company stock valued at $4,584,508. 3.92% of the stock is currently owned by company insiders.

Twist Bioscience Stock Up 0.2 %

NASDAQ:TWST opened at $47.50 on Friday. The company has a market cap of $2.82 billion, a P/E ratio of -13.19 and a beta of 1.82. The firm’s 50 day moving average is $44.94 and its two-hundred day moving average is $46.63. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TWST. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Leerink Partners upped their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. TD Cowen reaffirmed a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.